Solventum Corporation

Solventum Corporation

SOLVNYSE / NASDAQHealthcareLarge cap

$84.50-$1.30 (-1.5%)

Last close · Data as of Nov 20, 2026

Market cap
$14.3B
P/E
9.2x
EV / EBITDA
7.2x
Revenue
$8.3B
Net margin
18.7%
ROCE
5.7%

+6.3% over the last year

Solventum Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-2.2%
3M
-4.6%
6M
+11.0%
1Y
+6.3%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$1.30 (-1.5%) from $86 to $85 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SOLV, bought on each weekday since 2024.

News & filings

What Solventum filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was 0.24 times net profit in fiscal 2025.

Strengths (1)

  • EBITDA grew 66.9% in fiscal 2025, 66.1 points more than revenue.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.

Read moreShow less

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

Sector
Healthcare
Shares outstanding
174.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$14.3B
P/E
9.2x
P/B
2.8x
EV / EBITDA
7.2x
EV / Sales
2.2x
P/S
1.7x
52-week high
$92.44
52-week low
$62.49

Profitability

Operating margin
7.6%
Net margin
18.7%
EBITDA margin
30.6%
ROE
30.8%
ROCE
5.7%
ROA
10.9%
Asset turnover
0.58

Growth

Revenue
$8.3B
Revenue growth, 1Y
0.9%
Revenue CAGR, 3Y
0.8%
Net profit growth, 1Y
224.8%
Free cash flow
-$10.0M

Solvency

Current ratio
1.23
Debt / Equity
1.00
Debt / Assets
0.35
CFO / Net profit
0.24
Cash / Market cap
6.2%

Where the revenue went

Of every $100 of FY2025 revenue, $19 was left as net income.

Solventum Corporation income statement flow, FY2025
Solventum Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$3.9B
RevenueGross profit$4.5B
Gross profitResearch and development$739.0M
Gross profitSelling, general and administrative$3.1B
Gross profitOperating income$632.0M
Operating incomePretax income$632.0M
Interest and other incomePretax income$1.1B
Pretax incomeTax and other$157.0M
Pretax incomeNet income$1.6B

Revenue and net profit

Revenue grew 0.9% in FY2025; net profit is the dashed line.

Solventum Corporation revenue and net profit by fiscal year
Solventum Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$8.1B$1.3B
FY2023$8.2B$1.3B
FY2024$8.3B$479.0M
FY2025$8.3B$1.6B

Cash flows

FY2025: $369.0M from operations, -$10.0M free after investment (dashed).

Solventum Corporation operating and free cash flow by fiscal year
Solventum Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.7B$1.4B
FY2023$1.9B$1.6B
FY2024$1.2B$805.0M
FY2025$369.0M-$10.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$8.3B+0.9%1Y
EBITDA
$2.5B+66.9%1Y
Net profit
$1.6B+224.8%1Y
Cash from operations
$369.0M-68.9%1Y
Free cash flow
-$10.0M-101.2%1Y
Revenue CAGR, 3Y
0.8%
Net profit CAGR, 3Y
5.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$8.3B$2.5B$1.6B-$10.0M30.8%+0.9%+224.8%

Monthly returns

Month-by-month returns of SOLV across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$14.3B
Liabilities$9.2B
Equity$5.0B
Paid-in capital$3.9B
Retained earnings$1.8B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SOLV highlighted.

P/E against peers

SOLV trades at 9.2x earnings against a peer median of 23.8x (a 61% discount).

Not shown (no positive earnings and no EV / Sales): Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Solventum CorporationSOLVthis companyP/E ↓ discount$14.3B9.2x2.8x30.8%7.2x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Zimmer Biomet Holdings, Inc.ZBH$16.8B23.8x1.3x5.6%10.7x
DaVita Inc.DVA$12.3B16.5x-18.9x-114.7%9.3x
The Cooper Companies, Inc.COO$12.1B32.3x1.5x4.6%13.9x
Align Technology, Inc.ALGN$12.1B29.4x3.0x10.1%13.5x
Insulet CorporationPODD$10.1B41.0x6.7x16.3%21.2x
Universal Health Services, Inc.UHS$8.6B5.8x1.2x20.5%5.0x
Peer median—23.8x1.4x7.8%10.7x

Year-to-date ROI

SOLV since 1 January, against earlier years.

Historical volatility

SOLV's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Solventum Corporation operating margin by fiscal year
Solventum Corporation operating margin by fiscal year
DateOperating margin
FY202220.8%
FY202320.0%
FY202412.6%
FY20257.6%
LineFY2025
Cost of revenueCost Of Revenue$3.9B
Gross profitGross Profit$4.5B
Operating expensesOperating Expense$3.8B
Research and developmentResearch And Development$739.0M
Selling, general and administrativeSelling General And Administration$3.1B
Rent expense supplementalRent Expense Supplemental—
Total expensesTotal Expenses$7.7B
Pretax incomePretax Income$1.7B

Learn while you research

Academy chapters picked for Solventum Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 9.2 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →